Principal Investigator
Breisacher Str. 115
79106 Freiburg
| 2010–2017 | Medical School, University of Freiburg, Germany, Medical University of Vienna, Austria, University of South Florida, Tampa, USA, Charité Berlin, Germany |
| 2018 | Doctorate in Medicine, University of Freiburg, Freiburg, Germany. Highest distinction (summa cum laude). Prof. Dr. Robert Zeiser/ Prof. Dr. Marcel van den Brink (Memorial Sloan Kettering Cancer Center) |
| Since 2024 | Clinician Scientist, Department of Tumor Immunology and Immune Regulation (Director Prof. Dr. Robert Zeiser) and Department of Medicine I (Hematology, Oncology and Stem Cell Transplantation), Director: Prof. Dr. Justus Duyster, University Medical Center Freiburg, Freiburg, Germany |
| 2021–2024 | Postdoctoral Research Fellow/ Research Associate and Guest Physician, Institute of Experimental Immunology, Laboratory of Prof. Dr. Burkhard Becher, PhD, University of Zurich and Department of Hematology and Medical Oncology, University Hospital Zurich, Zurich, Switzerland |
| 2018–2021 | Resident physician, Department of Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany |
| 2013–2015 | Graduate Research Assistant, Laboratory of Prof. Dr. Marcel van den Brink, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, USA |
| 2025 | Max Eder Stipend (Deutsche Krebshilfe) |
| 2024 | Computational Biology Training in Hematology Award, EHA and EMBL-EBI |
| 2024 | Berta Ottenstein Clinician Scientist Program |
| 2024 | John Hansen Research Grant (DKMS) |
| 2023 | Abstract Achievement Award (American Society of Hematology) |
| 2023 | Young Investigator Award, Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Oncology |
| 2021 | Hans Jochem Kolb Award for Advances in Allogeneic Stem Cell Transplantation, GvL GvH Conference, Regensburg (Germany) |
| 2021–2023 | Walter-Benjamin Fellowship of the Deutsche Forschungsgemeinschaft |
| 2020 | ReForm A Fellowship for Young Investigators, University of Regensburg |
| 2019 | Regensburg Oncology Award (Comprehensive Cancer Center Regensburg) |
| 2018 | Jon J. van Rood Award (EBMT with E. Velardi and J. Tsai) |
| 2014 | Abstract Achievement Award (American Society of Hematology) |
| 2013–2014 | MD Fellowship, Boehringer Ingelheim Fonds |
| 2012–-2017 | Scholar of the German National Academic Foundation (Studienstiftung des deutschen Volkes) |
Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.